Clinical Trial Update: A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies [Phase 2]

View source ↗

Summary

This clinical trial update reports on a Phase 2 study of XmAb20717 (Vudalimab) in selected advanced gynecologic and genitourinary cancers, with current status A…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Cervical Carcinoma
• Clear Cell Carcinoma
• Endometrial Cancer
• Ovarian Cancer

Drugs mentioned

• Vudalimab (XmAb20717) (Vudalimab)

Snippet

Sponsor: Xencor, Inc. | Conditions: Ovarian Cancer, Clear Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING